News

Siren Biotechnology Awarded $4M in Grant Funding from the California Institute for Regenerative Medicine (CIRM)

Siren Biotechnology, a gene therapy company pioneering Universal AAV Immuno-Gene Therapies for Cancer™, announced today that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $4M translational research grant to support the development of novel AAV immuno-gene...

AbbVie Exercises Exclusive Right to Acquire Mitokinin

AbbVie announced today that it has exercised its exclusive right and completed the acquisition of Mitokinin, a discovery-stage biotechnology company developing a potentially first-in-class disease-modifying treatment for Parkinson's Disease (PD). Mitokinin's lead compound, a selective PINK1...

Sonoma Biotherapeutics Appoints Joseph R. Arron, M.D., Ph.D., as Chief Scientific Officer and Mark D. Eisner, M.D., MPH, as Chief Medical Officer

“Joe and Mark have established track records of driving scientific and clinical strategy to advance novel therapies for patients living with devastating diseases,” said Jeff Bluestone, Ph.D., Co-founder and Chief Executive Officer of Sonoma Biotherapeutics. “We look forward to leveraging their...

Regel Therapeutics Awarded $1 Million from HS Chau Women in Enterprising Science Program

Regel Therapeutics, a next-generation gene therapy company utilizing proprietary technology to modulate gene expression, today announced that based upon the groundbreaking work of its Co-Founder and Chief Scientific Officer Dr. Navneet Matharu it has been selected to receive $1 Million in non-...

Rezo Therapeutics Appoints Nadir Mahmood, Ph.D., as Chief Executive Officer

Rezo Therapeutics, a biotechnology company pioneering the integrated mapping of disease networks for precision therapeutics, today announced the appointment of Nadir Mahmood, Ph.D., as chief executive officer and board member. Dr. Mahmood previously served as chief financial and business officer of...

Myeloid Therapeutics Initiates Patient Dosing with MT-302, a Novel TROP2-Targeting RNA CAR, in Phase 1 Study for Advanced or Metastatic Epithelial Tumors

Myeloid Therapeutics, a clinical-stage oncology company, has dosed the first patient with MT-302 in a Phase 1 study for advanced or metastatic epithelial tumors. MT-302 is the Company’s lead development candidate for in vivo immune cell programming and delivers TROP2-targeting RNA chimeric antigen...

Exai Bio Presents Data Further Validating its Liquid Biopsy Platform at the 2023 World Conference on Lung Cancer

Exai Bio today announced non-small cell lung cancer (NSCLC) data further validating that its novel RNA- and generative AI-based liquid biopsy platform detected early-stage disease with high accuracy. The study of nearly 900 subjects demonstrated stage I sensitivity was 95% at 90% specificity.

Viz.ai Signs License Agreement with UCSF to Commercialize Three Cardiac Artificial Intelligence Algorithms

Viz.ai, working in AI-powered disease detection and intelligent care coordination, today announced that it has signed an exclusive agreement with the University of California, San Francisco (UCSF) to commercialize three AI algorithms for the automated detection of cardiovascular diseases.

ClearPoint Neuro Announces Exclusive Multi-Year Licensing Agreement with UCSF for Innovative Intra-Cerebral Cellular Delivery Platform

UCSF and ClearPoint Neuro announce partnership to develop an innovative cellular delivery platform from the lab of Dr. Daniel Lim, MD, PhD via an exclusive multi-year licensing agreement. Bringing together UCSF's technology with the ClearPoint system will enable precise and targeted therapeutic...

Foundery Announces Initial Close of Inaugural Biotech Venture Creation Fund to Accelerate the Development of Novel Immunotherapies

Foundery, a biotechnology venture studio focused on transla6ng immunology discoveries into drug candidates, today announced an initial close of its inaugural fund, Foundery I, LP (“Foundery Fund I”), with total capital commitments and contributed assets as of the closing equal to $29.6 million.